Discover
etrolizumab (RG7413) / RocheEtrolizumab: Final data from P3 BERGAMOT trial (NCT02394028) for moderate-to-severe Crohn's disease in 2021 (Roche) - Sep 15, 2020 - Roche Pharma Day 2020 [Screenshot] Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic UniversityOCTAVE: Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis (clinicaltrials.gov) - Sep 15, 2020 - P3; N=944; Completed; Sponsor: Pfizer; Active, not recruiting --> Completed ontamalimab (SHP647) / TakedaEfficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) (clinicaltrials.gov) - Sep 14, 2020 - P3; N=40; Active, not recruiting; Sponsor: Shire; Recruiting --> Active, not recruiting; N=983 --> 40; Trial completion date: Aug 2022 --> Jun 2021; Trial primary completion date: Aug 2022 --> Jun 2021 etrasimod (APD334) / ArenaArena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis (Arena Press Release) - Sep 16, 2020 - "We are pleased to initiate the ELEVATE UC 12 Phase 3 trial...This is a significant milestone for Arena as the progress confirms that the ELEVATE UC registrational program, including ELEVATE UC 12 and UC 52 trials, remains on track for data by year-end 2021." ontamalimab (SHP647) / TakedaFIGARO UC 303: An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Sep 14, 2020 - P3; N=366; Active, not recruiting; Sponsor: Shire; Recruiting --> Active, not recruiting; N=696 --> 366; Trial completion date: Jun 2024 --> Jun 2021; Trial primary completion date: Jun 2024 --> Jun 2021 Rinvoq (upadacitinib) / AbbVieU-Accomplish: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Sep 14, 2020 - P3; N=523; Active, not recruiting; Sponsor: AbbVie; Recruiting --> Active, not recruiting
